|Bid||4.5800 x 1100|
|Ask||5.2500 x 800|
|Day's Range||4.8800 - 4.9900|
|52 Week Range||2.7600 - 15.9900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.33|
Multifactorial liver and systemic biological activity seen for both AXA1125 and AXA1957 in adult subjects with NAFLD at 16 weeks with onset as early.
A Cambridge startup is launching the local biotech industry’s first IPO of the year, just one month after raising $85 million from investors.
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the third quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based on its groundbreaking work on the human commensal virome. Ring's technology promises to address many of the limitations of current DNA and gene therapies, such as limited access to diverse tissues, inability to redose, risk of genomic integration, and poor tolerability. Ring's founding and continued development are resourced by an initial capital commitment of $50 million from Flagship Pioneering.
Even if it's not a huge purchase, we think it was good to see that David Epstein, the Chairman of Axcella Health Inc...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Successfully completed initial public offering, raising $71.4 million in gross proceedsPresented data on AXA1665 and AXA1125 at two leading medical conferencesIdentified drug.